In 2015, global funding for HIV prevention R&D declined slightly, from US $1.25 billion in 2014 to US $1.20 billion in 2015. This continues a decade of roughly flat funding. The US public sector remained the largest global contributor at US $850 million, and together with the Bill & Melinda Gates Foundation, the largest philanthropic funder, constituted 81 percent of all funding.
Global HIV Prevention R&D Investments by Technology, 2000-2015
Biomedical Prevention in 2016 – At a Glance
A snapshot of prevention strategies underway or under development from 2015-2020. Excerpted from AVAC Report 2016: Big Data, Real People.
HIV Prevention Research Status Report
A survey of prevention strategies and the status of their safety and efficacy. Excerpted from AVAC Report 2016: Big Data, Real People.
Progress Toward an Vaccines
This one-page infographic from NIAID highlights challenges and progress in the search for a vaccines, and also includes brief descriptions of some of the approaches to vaccine development that scientists are exploring today.
Vaccines Clinical Trials Snapshot
Excerpted from our quick, colorful and comprehensive vaccines research four-pager, the centerspread tracks the current status and future possibilities of all potential vaccines approaches being test. The centerspread also has a list of what advocates’ should be on the lookout for.
bNAb Targets on HIV
Scientists have mapped the shape and structure of bNAbs and identified points of contact and binding with the envelope trimer, shown in this graphic. Understanding the shape of the binding sites for bNAbs is key to vaccine development.
The Number of Vaccines Trials (2016)
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
Vaccine Strategies in Clinical Trials (2016)
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
Number of Broadly Neutralizing Antibodies Discovered
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
Vaccines Clinical Trial Participants by Region
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.